A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis

INTRODUCTION: Upadacitinib and tofacitinib are Janus kinase inhibitors approved for moderate-to-severe rheumatoid arthritis (RA). In the absence of head-to-head trials comparing their effectiveness, this study assessed the efficacy of upadacitinib 15 mg once-daily monotherapy/combination therapy aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Christopher J., Sawant, Ruta, Garg, Vishvas, Du, Ella X., Friedman, Alan, Betts, Keith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991064/
https://www.ncbi.nlm.nih.gov/pubmed/33244703
http://dx.doi.org/10.1007/s40744-020-00257-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991064/
https://www.ncbi.nlm.nih.gov/pubmed/33244703
http://dx.doi.org/10.1007/s40744-020-00257-w

Ejemplares similares